Key facts
- This page summarizes Mark K. Oki's Form 4 filing for AYTU BIOPHARMA, INC (AYTU).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 15 Aug 2023, 19:28.
Mark K. Oki - 11 Aug 2023 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- AYTU
- Reported as of
- 11 Aug 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Aug 2023, 19:28:59 UTC
- Prior SEC filing
- 28 Nov 2022
- Next SEC filing
- 09 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark K. Oki
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark K. Oki filed Form 4 for AYTU BIOPHARMA, INC (AYTU) on 15 Aug 2023.
Change
- Previous filing in this sequence was filed on 28 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AYTU
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +13,000
- Change %
- Price
- $0.000000
- Shares after
- 13,000
- Date
- 11 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 13,000
- Exercise price
- $1.73
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options vest as follows: 1/3 on August 11, 2024, with the remaining options vesting in 24 equal monthly installments beginning September 11, 2024.